OPRX (Health Care Technology) Stock Valuation & Fair Value Quality business with a solid forward outlook
OPRX (Health Care Technology) trades at a blended P/E of 6.9, about 92% below its historical normal valuation, with a forward growth estimate of 5.6% and a PEG of 1.23. Analysts' one-year estimates have been hit 18% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is OPRX overvalued?
At a blended P/E of 6.9 versus its historical normal P/E of 85.9, OPRX trades about 92% below its typical valuation, with a PEG of 1.23 on 5.6% forward growth. tickerseer currently rates it quality business with a solid forward outlook.
What is OPRX's fair value and PEG?
OPRX trades at a blended P/E of 6.9 against a historical normal P/E of 85.9, a PEG of 1.23, and a forward growth estimate of 5.6%.
Has tickerseer's rating of OPRX changed?
tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.
Industry: Health Care Technology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.